A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2/3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
314actual
Sites
68
Countries
Belgium, Czechia, Denmark +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-27 | actual | When the study began enrolling |
| Primary completion | 2026-01-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-16 | actual | The whole study's end, after follow-up |
| First posted | 2018-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hypertrophic Cardiomyopathy
- Obstructive Hypertrophic Cardiomyopathy
- Non-obstructive Hypertrophic Cardiomyopathy
Intervention
- Drug: mavacamten — also filed as MYK-461
Primary outcome
what the primary-completion date above is the date OFFrequency and severity of treatment-emergent adverse events and serious adverse events
measured 252 weeks
Publications
- PMID 38176782 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed